Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

New Haven Pharmaceuticals

Request full access

Welcome to New Haven Pharmaceuticals | New Haven Pharmaceuticals

North Haven, United StatesFounded 2008Biotech & Life Sciences

About New Haven Pharmaceuticals

New Haven Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary prescription drugs. The company's strategy involves utilizing well-established compounds, including those designated as Generally Recognized as Safe (GRAS), in combination with its proprietary controlled-release technologies to create new pharmaceutical products.

One of the company's notable achievements is the development and FDA approval of Durlaza, an extended-release aspirin capsule. This product is indicated for the secondary prevention of stroke and other acute cardiac events, targeting patients with cardiovascular disease. By creating a controlled-release formulation of a widely used and well-known drug like aspirin, New Haven Pharmaceuticals aims to offer improved therapeutic options for patients.

The company operates in the competitive pharmaceutical market, with a business model centered on the research, development, and commercialization of its proprietary drug formulations. As a privately held entity, its financial success is tied to the market adoption and sales of its products like Durlaza, which are prescribed by healthcare professionals and distributed through pharmacies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
57.4/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Risk Management, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBT✓Debt Aug 2016 $600K — Undisclosed —
DEBT✓Debt Oct 2015 $6.3M — Horizon Technology Finance Corporation —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

New Haven Pharmaceuticals website traffic

Latest recorded traffic for New Haven Pharmaceuticals is 1.6K monthly website visits, up 190.9% over the last three months. New Haven Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits1.6K 3-month web change+190.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

New Haven Pharmaceuticals in the North Haven ecosystem

Live from Dealroom

The New Haven Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Kuzari Group
  • Connecticut Innovations
  • EJ Funds
  • Yale School of Management
  • Yale Law School

Series B and later2 investors entered at this stage

  • Advantage Capital
  • Horizon Technology Finance Corporation

Other known investors1 additional known investor

  • Yale University
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about New Haven Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See New Haven Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.